See original story here HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) — IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on the Nasdaq Capital Marketunder the symbol “IMV.” Trading will commence as early as Friday, June 1, 2018. The Corporation will retain its listing…

See original story here Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that it will participate in this year’s annual Bloom Burton & Co. Healthcare Investor Conference. The conference takes place May 2-3, 2018 in Toronto, Canada. Appili’s Chief Executive Officer Kevin Sullivan will present a corporate overview…

2015 © Copyright - Bionova